7 Drugs Approved for Primary Care: Q3 2024

News
Slideshow

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

As another quarter rounds out, a new batch of drugs have been approved by the US FDA for conditions often seen in primary care. Below, find details on the updated 2024-2025 formulations of mRNA COVID-19 vaccines, the first and only needle-free treatment alternative to epinephrine injection, the first orally disintegrating tablet to receive FDA approval for pregnancy prevention, and 4 more.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Related Content
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

Sydney Jennings;Johann Gudjonsson, MD, PhD
June 12th 2025
Article

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

Sydney Jennings;Elizabeth Mollard, PhD
May 22nd 2025
Podcast

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Sydney Jennings
June 11th 2025
Article

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed

2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed

Sydney Jennings
June 10th 2025
Article

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During first RVS Season image credit ©Waldenmarus/stock.adobe.com

Clesrovimab Wins FDA Approval for Prevention of RSV LRTD in Infants During First RSV Season

Grace Halsey
June 10th 2025
Article

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

© 2025 MJH Life Sciences

All rights reserved.